Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PhRMA Close To Deal With Tauzin; Changes In Reg Affairs, PR Line Up

Executive Summary

The Pharmaceutical Research & Manufacturers of America is understood to be close to finalizing an agreement with Rep. Billy Tauzin (R-La.) to take over as the new CEO of the trade group

You may also be interested in...



PhRMA Readies “Access & Affordability” Campaign; PR Overhaul Complete

The Pharmaceutical Research & Manufacturers of America is establishing an internal group on drug access and affordability in preparation for launching a nationwide public educational effort on the theme

PhRMA Readies “Access & Affordability” Campaign; PR Overhaul Complete

The Pharmaceutical Research & Manufacturers of America is establishing an internal group on drug access and affordability in preparation for launching a nationwide public educational effort on the theme

PhRMA CEO Tauzin Takes Over Jan. 3: PR Focus Begins At The Top

PhRMA's new management team under CEO Billy Tauzin will place a high priority on communications and partnerships with other stakeholders in healthcare policy debates

Related Content

UsernamePublicRestriction

Register

LL016789

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel